Federal authorities say the scheme generated large volumes of alleged false billing tied to skin-substitute products, provider profit arrangements, disputed acquisition-price reporting, and commissions connected with government reimbursements across a nearly seven-year operation involving multiple Nevada companies and participating medical practices.
WASHINGTON, DC — A federal indictment accuses Las Vegas businessman Michael McMillan of directing a sprawling skin-substitute operation that allegedly caused Medicare, TRICARE, and CHAMPVA to pay approximately $268 million on fraudulent wound-care claims submitted through participating medical practices.
Prosecutors say the alleged operation transformed expensive wound products into a reimbursement-driven business model, combining no-upfront-cost inventory, billing assistance, provider profit shares, sales commissions, and disputed acquisition-price representations across transactions extending from May 2019 through at least February 2026.
The government has not proved those accusations, McMillan remains presumed innocent, and the approximately $268 million figure represents alleged program payouts identified in the charging document rather than a judicially established loss or final restitution amount.
That distinction matters because headlines can blur submitted charges, approved reimbursements, alleged proceeds, provider profits, seized property, and possible forfeiture, even though each category answers a different financial question and may be contested through evidence, expert analysis, and court rulings.
At its center, the case asks whether a network marketed clinically useful products through unlawful financial incentives and false billing information, or whether prosecutors have mischaracterized complicated discounting, credit, collections, reimbursement, and sales practices operating within a highly regulated healthcare marketplace.
What the $268 Million Figure Actually Represents
According to the federal indictment against Michael McMillan, McMillan and companies collectively described as Protectus allegedly caused government programs to fraudulently pay approximately $268 million for skin-substitute claims connected with recruited physicians, podiatrists, nurse practitioners, and other providers.
The indictment does not publicly calculate the aggregate face value of every claim submitted, every amount denied, or every product ordered, meaning the stated figure should be reported as alleged payments rather than automatically labeled total attempted billing.
That difference can be substantial in healthcare prosecutions because providers may submit claims that are reduced, denied, returned, suspended, appealed, or repaid, while loss calculations can change depending upon medical value, kickback taint, material falsity, sampling methods, and governing law.
Prosecutors nevertheless portray the $268 million reimbursement stream as the scheme’s financial engine, alleging that paid claims supplied the money divided among medical providers, Protectus companies, sales representatives, and later transactions involving valuable real estate, vehicles, and an aircraft.
How Skin Substitutes Entered the Billing System
Skin substitutes are advanced wound-care products that can support healing for qualifying chronic ulcers when clinicians document medical necessity, conservative treatment, wound characteristics, application details, product usage, wastage, patient response, and follow-up under applicable coverage requirements.
Their clinical legitimacy is not itself disputed by the mere existence of an indictment, because a properly selected and documented product can benefit a patient even when investigators separately question pricing, referral incentives, billing accuracy, or the commercial relationship surrounding reimbursement.
The McMillan case instead focuses upon how products were supplied, how participating practices were recruited, what economic risk providers actually carried, what acquisition-price information appeared on claims, and how successful government payments were divided after adjudication.
Federal authorities contend those elements operated as a coordinated system, not independent administrative conveniences, because the alleged profit promises and billing support purportedly encouraged providers to use products reimbursed by taxpayer-funded healthcare programs.
No Upfront Payment and No Charge After Denial
The indictment alleges that Protectus supplied skin substitutes without requiring medical practices to pay upfront, allowing providers to apply costly products and seek reimbursement before becoming responsible for the inventory under the financial arrangement described by prosecutors.
When Medicare, TRICARE, or CHAMPVA denied a claim, Protectus allegedly did not charge the provider for the associated product, shifting denial risk away from the practice and eliminating a financial consequence normally present when purchased inventory remains payable.
When a claim succeeded, however, Protectus allegedly invoiced approximately 60 percent to 70 percent of the reimbursement, leaving the provider with approximately 30 percent to 40 percent and potentially thousands of dollars after each paid application.
The government characterizes that retained amount as unlawful remuneration disguised as discounts, rebates, and profits, while the defense may argue the arrangement reflected lawful net pricing, commercial credit, collection risk, or negotiated concessions.
Provider Profits Allegedly Drove Product Selection
Prosecutors allege that McMillan and participating representatives marketed the opportunity for substantial provider profit, making the anticipated government reimbursement and retained percentage central features of recruitment rather than incidental consequences of ordinary product purchasing.
That theory treats the provider margin as an inducement tied to federally reimbursable orders, because practices allegedly received products without upfront payment, owed nothing after denials, and kept a predetermined share whenever the government paid.
Financial benefit alone does not establish an illegal kickback, yet arrangements linked to the volume or value of federal healthcare business can create serious exposure when prosecutors prove remuneration was knowingly offered or paid to influence ordering decisions.
The defense can examine whether contracts disclosed pricing, whether providers exercised independent clinical judgment, whether discounts were properly structured and reported, whether legal advice supported the model, and whether prosecutors have treated ordinary commercial negotiations as criminal inducements.
The Alleged Acquisition-Price Misrepresentation
Beyond kickbacks, the indictment alleges that claims included false acquisition-price information by failing to reflect discounts, rebates, refunds, and other adjustments that reduced what providers actually expected to pay Protectus for the supplied skin-substitute products.
Prosecutors focus upon information entered in Box 19 of certain Medicare claims, contending that the reported figure did not represent the provider’s true economic obligation after the reimbursement-sharing arrangement and denial protections were considered together.
That allegation supplies a direct false-billing theory because government programs use submitted information to determine payment eligibility and amounts, while providers certify that their claims are truthful, accurate, medically supported, and compliant with applicable program requirements.
McMillan’s defense may challenge which entity prepared particular entries, whether providers controlled final submissions, what written guidance applied, whether acquisition cost was reasonably interpreted, and whether any disputed statement was knowing, material, and connected with program payment.
A Texas Claim Example Described by Prosecutors
The indictment describes a May 2024 episode involving a Texas podiatrist whose practice allegedly received payment on one skin-substitute claim while another claim was denied, illustrating how Protectus purportedly matched its invoice obligations to insurer outcomes.
A Protectus employee allegedly advised the practice that a paid claim missing Box 19 information required resubmission using details from a company spreadsheet, placing company personnel close to the pricing representation federal investigators challenged.
After the provider reported receiving $9,024, Protectus allegedly issued an invoice for $5,865, which represented 65 percent of that payment, while the product connected with the denied claim generated no comparable immediate charge under the alleged arrangement.
One selected transaction cannot prove the scope of a national conspiracy, but prosecutors may use comparable invoices, messages, spreadsheets, remittances, and denials to argue that standardized procedures repeatedly connected company charges with successful government reimbursements.
Six Nevada Companies Under One Collective Name
The indictment collectively calls six Nevada limited liability companies Protectus, identifying Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC as entities McMillan allegedly owned and controlled.
McMillan is the defendant named in the nine-count indictment, while those companies appear as parts of the factual narrative rather than as separately charged corporate defendants, an important distinction for accurate reporting on responsibility and procedural status.
Prosecutors repeatedly refer to actions by McMillan and Protectus, alleging that the connected businesses supplied products, recruited providers, supported billing, tracked reimbursements, calculated percentage-based invoices, collected payments, prepared commission reports, and compensated representatives.
The defense can seek entity-specific records showing separate purposes, employees, contracts, accounts, tax treatment, and compliance responsibilities, because common ownership and coordinated operations do not, by themselves, establish that every company knowingly participated in unlawful conduct.
An Alleged Scheme Lasting Nearly Seven Years
Federal prosecutors place the beginning of the charged conspiracies around May 2019 and allege that the conduct continued through at least February 2026, creating a lengthy period across which policies, personnel, products, providers, and reimbursement guidance may have changed.
For the government, duration can support an inference of institutional knowledge when similar pricing formulas, denial practices, commission structures, and billing instructions recur across years, practices, states, employees, and separate corporate accounts under common leadership.
For the defense, the same timeline may reveal materially different arrangements, revised contracts, isolated mistakes, employee departures, compliance interventions, legitimate revenue, or substantial periods when the practices prosecutors describe did not occur consistently.
The charging document identifies participating providers and representatives through anonymous letters, allowing prosecutors to outline transactions without publicly naming every witness while leaving their complete roles, credibility, incentives, and potential exposure for later litigation.
Medicare, TRICARE, and CHAMPVA Were Allegedly Affected
Medicare serves older adults and qualifying people with disabilities, TRICARE provides coverage for eligible military communities, and CHAMPVA supports qualifying spouses, children, survivors, and caregivers connected with veterans, giving the alleged billing broad public significance.
Although each program operates under distinct statutes, contractors, payment systems, and administrative rules, prosecutors allege that all three reimbursed skin-substitute claims arising from the challenged commercial model during the period described in the indictment.
The government contends that claims resulting from illegal healthcare kickbacks were ineligible for payment and that inaccurate acquisition-price representations further undermined program decisions, creating overlapping theories of falsity, causation, materiality, and financial harm.
McMillan may dispute whether particular claims were medically necessary, whether any remuneration induced ordering, whether pricing statements were false, whether program rules gave adequate notice, and whether every reimbursement within the aggregate figure shared the same alleged defect.
How Prosecutors Divide the Alleged Payment Stream
The indictment alleges that approximately $94 million of the $268 million remained with medical providers through the claimed 30-percent-to-40-percent profit shares, amounts the government characterizes as kickbacks rather than permissible margins or documented discounts.
Protectus companies allegedly received approximately $174 million through invoices following successful claims, a figure representing their asserted share of program reimbursements before accounting for product costs, payroll, taxes, refunds, commissions, overhead, transfers, or any legitimate revenue adjustments.
Sales representatives allegedly received approximately $27 million in commissions tied to business generated through recruited providers, although that amount came from Protectus receipts and should not be added to $268 million as if it represented separate program payments.
Keeping those categories separate prevents inflated reporting, because the alleged provider shares and Protectus share divide the same reimbursement pool, while representative compensation, seized assets, transaction counts, and possible forfeiture describe later uses or subsets of money.
Sales Representatives and Reimbursement-Linked Commissions
Prosecutors allege that representatives recruited medical practices and earned commissions based upon reimbursements generated by those providers, creating an incentive structure that allegedly rewarded successful federal claims rather than merely compensating fixed-price product sales.
One representative allegedly questioned an omitted commission exceeding $6,400, and a Protectus employee reportedly explained that commissions could be paid only after the medical office confirmed it had received insurer payment on the underlying claim.
Another monthly report allegedly documented more than $120,000 paid to a Utah representative, including compensation connected with company profits from a provider invoice that divided a successful reimbursement according to the challenged percentage formula.
The defense may answer that commercial commissions commonly become payable only after customer collections, requiring prosecutors to prove that these payments were knowingly designed to induce federally reimbursable orders rather than reward lawful sales and completed accounts receivable.
Why Kickbacks Can Turn Otherwise Real Care into False Claims
Healthcare fraud cases do not always depend upon proving that nothing was delivered, because prosecutors can contend that a genuine product or service became nonpayable when an illegal kickback corrupted the ordering decision or violated a material payment condition.
That principle makes the McMillan allegations different from a simple phantom-billing case, since the indictment describes actual products, provider applications, insurer adjudication, invoices, and collections while challenging the financial conditions surrounding those transactions.
Evidence that patients received treatment may therefore influence medical-necessity, value, and loss disputes without automatically defeating a kickback theory, just as evidence of high reimbursement cannot independently prove that clinicians abandoned legitimate judgment.
Jurors may eventually need to separate clinical benefit from payment eligibility, determining whether specific applications helped patients while also deciding whether remuneration or pricing representations knowingly caused programs to pay claims they would otherwise reject.
Claims Data Could Reveal Scale and Repetition
Investigators can compare product codes, provider identifiers, beneficiary histories, application dates, wound diagnoses, reimbursement amounts, denial patterns, supplier invoices, Box 19 entries, and representative assignments to identify recurring relationships across millions of dollars in payments.
They can also align government remittances with practice deposits, Protectus invoices, provider checks, corporate receipts, commissions, refunds, and owner distributions, creating chronological maps that test whether the alleged percentage system operated as prosecutors describe.
Patterns may identify unusual growth or consistent profit ratios, but statistical abnormality remains an investigative signal rather than criminal proof because specialized practices, changing coverage, new products, legitimate referrals, or improved collections can also produce sharp increases.
The strongest evidence will combine analytics with contemporaneous contracts, emails, texts, spreadsheets, claim forms, clinical records, bank statements, and credible testimony, allowing factfinders to distinguish a purposeful scheme from mistakes, ambiguity, or lawful commercial activity.
The Nine Counts Extend Beyond False Billing
Count One charges McMillan with conspiracy to commit healthcare fraud, alleging an agreement to obtain program money through materially false representations and claims tied to kickbacks, rather than identifying every reimbursement as a separate, substantive offense.
Count Two alleges conspiracy to defraud the United States and pay healthcare kickbacks, focusing upon claimed efforts to impair Medicare administration while offering remuneration to providers and representatives connected with federally reimbursable product orders.
Counts Three through Nine allege monetary transactions exceeding $10,000 involving property derived from the two charged conspiracies, identifying payments associated with four real-estate properties, two luxury vehicles, and a private aircraft during the alleged scheme.
Those financial counts require transaction-specific proof and should not be described as automatic consequences of the $268 million allegation, because prosecutors must trace qualifying criminal proceeds and establish McMillan’s required knowledge for each listed payment.
Part of the 2026 National Enforcement Action
The McMillan indictment was announced during the Justice Department’s 2026 National Health Care Fraud Takedown, which charged 455 defendants across 56 federal districts in alleged schemes collectively involving more than $6.5 billion in false claims and significant patient harm.
Northern District of Texas authorities announced seven cases involving thirteen defendants and more than $365 million in alleged fraudulent billing, making McMillan’s approximately $268 million reimbursement matter the district’s largest disclosed case by payment amount.
An NBC 5 Dallas-Fort Worth report on the North Texas cases described allegations involving elderly patients, military families, wound products, laboratory services, neurological procedures, hospice care, testing kits, and durable medical equipment throughout the region.
Federal officials credited the Federal Bureau of Investigation, the Department of Health and Human Services inspector general, the Defense Criminal Investigative Service, and the Department of Veterans Affairs inspector general with investigating the McMillan allegations.
Seizures Are Not Proof of False Claims
Authorities reported seizing about $35 million in cash, luxury vehicles, and other assets during the North Texas operation, while the McMillan indictment seeks forfeiture of specified property and a money judgment tied to alleged proceeds.
Pretrial seizure preserves disputed property and does not establish guilt, criminal origin, permanent forfeiture, or final value, because defendants and qualifying third parties may challenge tracing, ownership, liens, valuation, commingling, and substitute-asset theories.
Likewise, recognizable purchases involving a Lamborghini, a Cadillac Escalade, real estate, and a Cessna Citation aircraft can make a technical billing case vivid, but luxury imagery cannot substitute for proof of falsity, intent, causation, and proceeds.
Responsible reporting must therefore keep the approximately $35 million seizure figure distinct from $268 million in alleged program payments, approximately $174 million received by Protectus, approximately $94 million retained by providers, and approximately $27 million in commissions.
Compliance Lessons for Medical Practices
Medical practices should independently review every proposed commercial arrangement offering expensive products without upfront payment, denied-claim protection, reimbursement-based invoicing, guaranteed margins, distributor-controlled billing assistance, or profit percentages tied directly to government payment outcomes.
Providers remain fully and independently responsible for medical necessity, clinical documentation, truthful claim certifications, acquisition-cost disclosures, and kickback compliance even when a distributor supplies coding support, spreadsheets, reimbursement estimates, invoices, or experienced administrative personnel.
Contracts should identify fixed or objectively supported prices, explain all rebates and refunds, allocate denial risk transparently, and ensure that the amount reported to an insurer matches the provider’s genuine economic obligation under complete transaction terms.
Practices should carefully preserve product orders, shipping confirmations, application logs, wound photographs, measurements, treatment histories, invoices, credits, claim forms, remittance notices, denial correspondence, payment records, and legal guidance for every high-value reimbursed product.
Compliance Lessons for Distributors and Sales Teams
Distributors should avoid compensation structures that merely divide future government reimbursement, especially when providers carry almost no downside and sales representatives receive larger commissions as federal claim values, application volumes, or successful collections increase.
Sales training should prohibit promises of guaranteed provider profit, require accurate discussion of reimbursement uncertainty, separate clinical education from financial inducements, and direct complicated pricing or coding questions through qualified compliance and legal review.
Affiliated companies should document why each entity exists, which employees act for it, what services it performs, how intercompany payments are calculated, and which organization owns inventory, contracts, billing tools, customer relationships, and compliance responsibilities.
Multiple companies are not inherently suspicious, but unclear boundaries can magnify enforcement risk when common personnel, shared accounts, centralized instructions, inconsistent invoices, or undocumented transfers make an ordinary business explanation difficult to verify.
Internal Audits Should Follow One Claim Completely
A meaningful healthcare audit should trace sampled transactions from manufacturer pricing through distributor acquisition, product shipment, clinical application, claim preparation, insurer adjudication, provider collection, supplier invoice, discount adjustment, commission payment, and any later refund or transfer.
Auditors should reconcile every price representation with contracts, invoices, credits, rebates, free goods, replacement products, denied-claim policies, financing terms, and side communications, because nominal invoices may not reveal the purchaser’s complete economic obligation.
Compliance teams should also test whether provider usage changed sharply after recruitment, whether product selection followed reimbursement values, whether sales personnel accessed claims data, and whether denied applications consistently eliminated inventory costs for participating practices.
Documented and timely corrective action matters when weaknesses appear, including repayment analysis, claim holds, revised contracts, retraining, independent review, disciplinary measures, and voluntary disclosure decisions developed with qualified counsel under applicable legal protections.
Managing Public Scrutiny Without Distorting the Record
An indictment involving government healthcare programs and nine-figure allegations can immediately affect employees, lenders, landlords, manufacturers, providers, patients, and families, even though the accusation begins a criminal case rather than resolving disputed facts.
Amicus International Consulting’s crisis public-relations guidance emphasizes organized assessment and disciplined communication, principles that remain appropriate only when organizations preserve evidence, describe procedural status accurately, coordinate with qualified counsel, and avoid witness pressure, concealment, retaliation, or obstruction.
Its reputation-rebuilding resources similarly support sustained credibility through verifiable public information, requiring affected organizations to distinguish allegations from adjudicated facts while respecting legitimate journalism, accessible public records, regulatory obligations, court orders, and accountability.
No communications strategy can erase an authentic indictment or replace a legal defense, but precise timelines, corrected misinformation, authorized spokespeople, consistent terminology, and transparent procedural updates can reduce avoidable confusion while the evidence receives adversarial testing.
What Prosecutors Must Prove
To obtain convictions, prosecutors must establish the charged agreements, McMillan’s knowing participation, material falsehoods, unlawful remuneration, federal-program connections, and required intent through admissible evidence rather than relying upon company ownership, reimbursement size, rapid growth, or expensive purchases.
They must connect McMillan personally with challenged billing instructions and payment arrangements, explain how participating providers understood the model, and demonstrate why specific representations or benefits caused government programs to issue reimbursements they otherwise would withhold.
The government must also support aggregate figures with reliable claims analysis while proving the elements of charged offenses, because a large statistical estimate can illustrate scale without establishing knowledge, materiality, causation, and criminal responsibility for every transaction.
Witnesses may include providers, representatives, billers, accountants, employees, and investigators, but jurors must evaluate their documents, incentives, immunity agreements, financial exposure, memory, consistency, and potential responsibility before accepting contested accounts of the operation.
Questions Available to the Defense
McMillan’s attorneys can challenge billing-rule interpretations, search procedures, expert methods, claim sampling, provider independence, safe-harbor analysis, discount treatment, witness credibility, entity boundaries, proceeds tracing, venue, forfeiture claims, and the government’s characterization of legitimate product value.
They may argue that providers selected medically appropriate products, that pricing reflected lawful commercial risk, that employees misunderstood complicated instructions, that submitted figures were reasonable, or that isolated communications cannot establish a seven-year criminal agreement.
The defense can also demand claim-level distinctions, separating denied from paid submissions, medically supported from unsupported applications, accurately priced from disputed transactions, and lawful revenue from amounts prosecutors allege were generated through kickbacks or deception.
None of those arguments has been accepted merely because it may be raised, just as the indictment’s detailed allegations have not been proven merely because a grand jury found probable cause for charges.
What Happens Next in the McMillan Case
The prosecution will move through arraignment, discovery, pretrial motions, expert analysis, asset litigation, and possible negotiations, with nearly seven years of claims, corporate records, clinical files, communications, banking data, and product documentation potentially requiring extensive review.
Major disputes may concern whether reported acquisition prices were materially false, whether provider margins constituted kickbacks, whether products were medically necessary, whether Protectus receipts qualify as criminal proceeds, and how any defensible loss should be calculated.
The approximately $268 million allegation will remain a central measure of claimed scale, but responsible coverage should repeatedly explain that prosecutors describe program payments, not a final adjudicated loss and not necessarily the complete face value of submissions.
Until McMillan enters a valid guilty plea or prosecutors prove their case beyond a reasonable doubt, every false-claim, kickback, monetary-transaction, and forfeiture allegation remains unresolved, and Michael McMillan is entitled to the presumption of innocence.
